USANA Health Sciences (NYSE:USNA) Announces Earnings Results

USANA Health Sciences (NYSE:USNA) issued its earnings results on Tuesday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50), FiscalAI reports. The business had revenue of $223.27 million for the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%.

USANA Health Sciences Trading Up 0.2%

Shares of USNA traded up $0.05 during trading hours on Tuesday, reaching $22.89. 102,151 shares of the company’s stock traded hands, compared to its average volume of 119,658. USANA Health Sciences has a 12 month low of $16.60 and a 12 month high of $32.32. The stock has a market cap of $422.53 million, a PE ratio of 48.70, a price-to-earnings-growth ratio of 0.87 and a beta of 0.73. The firm’s 50 day simple moving average is $20.53 and its 200-day simple moving average is $19.77.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Joshua Foukas sold 3,791 shares of USANA Health Sciences stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 17,660 shares of company stock valued at $336,579 in the last ninety days. 0.82% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On USANA Health Sciences

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in USANA Health Sciences by 1.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after buying an additional 21,793 shares during the period. Vanguard Group Inc. increased its holdings in shares of USANA Health Sciences by 5.7% in the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after buying an additional 57,249 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of USANA Health Sciences by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after acquiring an additional 17,318 shares during the last quarter. Nantahala Capital Management LLC bought a new stake in shares of USANA Health Sciences in the 4th quarter valued at about $11,485,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in USANA Health Sciences by 22.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 353,946 shares of the company’s stock valued at $6,948,000 after acquiring an additional 65,867 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on USNA. Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.